D. Scott Coward Net Worth

The estimated Net Worth of D Scott Coward is at least $11.2 Milión dollars as of 30 April 2024. Mr. Coward owns over 67 units of Exact Sciences stock worth over $2,862,573 and over the last 10 years he sold EXAS stock worth over $3,227,738. In addition, he makes $5,066,320 as Senior Vice President, Chief Administrative Officer, General Counsel a Secretary at Exact Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Coward EXAS stock SEC Form 4 insiders trading

D has made over 46 trades of the Exact Sciences stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 67 units of EXAS stock worth $4,030 on 30 April 2024.

The largest trade he's ever made was exercising 169,109 units of Exact Sciences stock on 23 January 2019 worth over $10,843,269. On average, D trades about 9,564 units every 56 days since 2015. As of 30 April 2024 he still owns at least 44,644 units of Exact Sciences stock.

You can see the complete history of Mr. Coward stock trades at the bottom of the page.

D. Scott Coward biography

D. Scott Coward serves as Senior Vice President, Chief Administrative Officer, General Counsel, Secretary of the Company. He has served as our Senior Vice President, General Counsel and Secretary since January 2015 and as our Chief Administrative Officer since July 2018. He joined us from the global law firm K&L Gates LLP, where he practiced corporate and securities law and served as managing partner of the Raleigh, NC office. Prior to his tenure at K&L Gates, Mr. Coward served as General Counsel of Blue Rhino Corporation, a leading supplier of consumer propane-related products. Prior to Blue Rhino, Mr. Coward served as an Associate General Counsel at GE Medical Systems in Milwaukee, WI, and prior to that, as a partner at the Raleigh, NC law firm Smith Anderson Blount Dorsett Mitchell & Jernigan LLP. Mr. Coward earned a bachelor's degree in business administration from the University of North Carolina—Chapel Hill and a JD from Columbia Law School.

What is the salary of D Coward?

As the Senior Vice President, Chief Administrative Officer, General Counsel a Secretary of Exact Sciences, the total compensation of D Coward at Exact Sciences is $5,066,320. There are 3 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.

How old is D Coward?

D Coward is 55, he's been the Senior Vice President, Chief Administrative Officer, General Counsel a Secretary of Exact Sciences since 2018. There are 11 older and 13 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.

What's D Coward's mailing address?

D's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.

Insiders trading at Exact Sciences

Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania a Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.

What does Exact Sciences do?

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com

Complete history of Mr. Coward stock trades at Exact Sciences

Exact Sciences executives and stock owners

Exact Sciences executives and other stock owners filed with the SEC include:

• Kevin Conroy,
  Chairman of the Board, President, Chief Executive Officer
• Mark Stenhouse,
  General Manager - Screening
• Jeffrey Elliott,
  Chief Financial Officer
• D. Scott Coward,
  Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
• Jake Orville,
  General Manager - Pipeline
• Ana Hooker,
  Senior Vice President, Operations
• Graham Lidgard,
  Senior Vice President, Chief Scientific Officer
• Kevin T. Conroy,
  Chairman, Pres & CEO
• G. Bradley Cole,
  Gen. Mang. of Precision Oncology
• Mark Stenhouse,
  Advisor
• Graham P. Lidgard,
  Emeritus Chief Science Officer
• Jeffrey T. Elliott CFA,
  Exec. VP, CFO & COO
• D. Scott Coward,
  Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec.
• Kathleen Sebelius,
  Independent Director
• Andrew Slavitt,
  Director
• Pierre Jacquet,
  Independent Director
• Jake Orville,
  Gen. Mang. of Pipeline
• Ana Hooker,
  Sr. VP of Operations
• James Doyle,
  Independent Director
• Michael Wyzga,
  Independent Director
• Daniel Levangie,
  Independent Director
• Katherine Zanotti,
  Independent Director
• Thomas Carey,
  Independent Director
• Shacey Petrovic,
  Director
• Gisela Paulsen,
  General Manager - Precision Oncology
• Torsten Hoof,
  General Manager - International
• Freda Lewis-Hall,
  Independent Director
• Scott Johnson,
  Senior Vice President, Research and Development
• Vic Parker,
  Head of Sales
• Tim Caprez,
  Chief Compliance Counsel & VP
• Megan Jones,
  Associate Mang. of Investor Relations
• Dr. Scott C. Johnson Ph.D.,
  Chief Science Officer and Sr. VP of R&D
• Gary Frings,
  Chief Information Officer
• Lionel Sterling,
  Director
• John A. Fallon,
  Director
• David Thompson,
  Director
• G Bradley Cole,
  General Manager - Diagnostics
• Paul J Clancy,
  
• Michael J Barber,
  
• Eli Casdin,
  Director
• Anthony P Shuber,
  Executive Vice President
• John A Jr Mccarthy,
  Chief Financial Officer
• Don M Hardison,
  President, CEO and Director
• Barry M Berger,
  SVP, Chief Medical Officer
• William J. Megan,
  SVP, Finance & PFO
• John K Bakewell,
  Chief Financial Officer
• Jeffrey R Luber,
  General Counsel
• Edwin M Jr Kania,
  Director
• Charles R Jr Carelli,
  Prin. Acct. Off. & Corp. Ctlr.
• Patrick J Zenner,
  Director
• Stanley N Lapidus,
  Director
• John M Krayacich,
  SVP, Sales and Marketing
• Richard W Barker,
  Director
• Laura S Stoltenberg,
  Chief Commercial Officer
• Cornelius Iii Mcgillicudy,
  Director
• Harry W Wilcox,
  Senior Vice President and CFO
• Lance Willsey,
  Director
• Michael E Singer,
  Director
• Maneesh Arora,
  Vice President
• James P Connelly,
  Director
• Sally Crawford,
  Director
• Sarah Condella,
  EVP, Human Resources
• Timothy J Scannell,
  Director
• James Herriott,
  SVP, General Counsel & Sec
• Everett Cunningham,
  Chief Commercial Officer
• Jacob A Orville,
  EVP, GM, Screening
• Brian Baranick,
  EVP, GM, Precision Oncology